Indications and uses
Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.
Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.
Adults: Instill one or two drops of 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 1% solution if necessary.
Rx only
AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution) is an anticholinergic prepared as a sterile, borate buffered solution for topical ocular use. It is supplied in two strengths.
Chemical name:
2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride
MW=327.85 C17H25NO3 • HCl
The active ingredient is represented by the structural formula:

AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution) USP, 1% & 2%
Each mL contains: Active: Cyclopentolate Hydrochloride 10 mg (1%) or 20 mg (2%).
Preservative: Benzalkonium Chloride 0.1 mg (0.01%).
Inactives: Boric Acid, Edetate Disodium, Potassium Chloride (except 2% strength), Sodium Carbonate and/or Hydrochloric Acid may be added to adjust pH (3.0 to 5.5) and Purified Water USP.
This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.
AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution) should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.
For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% cyclopentolate hydrochloride ophthalmic solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes.
Mydriatics may produce a transient elevation of intraocular pressure.
The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma.
Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.
Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate.
Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.
Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (see WARNINGS).
Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported. Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.
Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.
Adults: Instill one or two drops of 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 1% solution if necessary.
AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution, USP) is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows:
AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%)
15 mL NDC 21695-883-15
DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed.
KEEP OUT OF THE REACH OF CHILDREN.
Akorn
Lake Forest, IL 60045
CP00N
Revised 05/08
Repackaged by:
Rebel Distributors Corp.
Thousand Oaks, CA 91320
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1298352 | AK-Pentolate 1 % Ophthalmic Solution | PSN | 1 |
| 1298066 | cyclopentolate HCl 1 % Ophthalmic Solution | PSN | 1 |
| 1298352 | cyclopentolate hydrochloride 10 MG/ML Ophthalmic Solution [AK-Pentolate] | SBD | 1 |
| 1298066 | cyclopentolate hydrochloride 10 MG/ML Ophthalmic Solution | SCD | 1 |
| 1298352 | AK-Pentolate 1 % Ophthalmic Drops | SY | 1 |
| 1298352 | AK-Pentolate 10 MG/ML Ophthalmic Solution | SY | 1 |
| 1298066 | cyclopentolate hydrochloride 1 % Ophthalmic Solution | SY | 1 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 21695-883-15 | 2019-09-24 | C162847 | 48780-1 | 934fe258-4d88-48b1-e053-8cdaa90a720a | AK-PENTOLATE™ Cyclopentolate Hydrochloride Ophthalmic Solution, USP -Sterile |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 21695-883-15 | AK-PENTOLATE | 15 mL in 1 BOTTLE, DROPPER | SOLUTION/ DROPS | 15 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 21695-883-15 | ML - Milliliter | 21695-883 | 980c26d1-7f40-4b22-a9ad-b026277c9efe | 1 | 2012-07-24 |
| 17478-100-02 | ML - Milliliter | 17478-100 | 03dfa6bc-6389-4d1a-a84f-e216c3968e35 | 1 | 2012-07-24 |
| 17478-100-12 | ML - Milliliter | 17478-100 | 290d9102-0e8b-4322-ad9c-9917263f2563 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Cyclopentolate Hydrochloride | ACTIVE INGREDIENT | 736I6971TE | 1 | |
| Cyclopentolate | ACTIVE MOIETY | I76F4SHP7J | 1 | |
| Benzalkonium Chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| Boric Acid | INACTIVE INGREDIENT | R57ZHV85D4 | 1 | |
| Edetate Disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| Hydrochloric Acid | INACTIVE INGREDIENT | QTT17582CB | 1 | |
| Potassium Chloride | INACTIVE INGREDIENT | 660YQ98I10 | 1 | |
| Sodium Carbonate | INACTIVE INGREDIENT | 45P3261C7T | 1 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 21695-883 | 21695-883-15 |
| 17478-100 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Cyclopentolate Hydrochloride | 736I6971TE | ACTIB |
| Benzalkonium Chloride | F5UM2KM3W7 | IACT |
| Boric Acid | R57ZHV85D4 | IACT |
| Edetate Disodium | 7FLD91C86K | IACT |
| Potassium Chloride | 660YQ98I10 | IACT |
| Sodium Carbonate | 45P3261C7T | IACT |
| Hydrochloric Acid | QTT17582CB | IACT |
| Water | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / PERINEURAL | ADJ PH | ||
| Potassium Chloride | POTASSIUM CHLORIDE | 660YQ98I10 | SUSPENSION / ORAL | NA | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SHAMPOO, SUSPENSION / TOPICAL | 1 %w/w | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAPERITONEAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / TOPICAL | ADJ PH | ||
| Sodium Carbonate | SODIUM CARBONATE | 45P3261C7T | TROCHE / ORAL | 375 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | CAPSULE / ORAL | 7 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | POWDER, FOR SUSPENSION / ORAL | 285 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / RESPIRATORY (INHALATION) | 0.01 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.4 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / URETERAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, EMULSION / INTRAVENOUS | ADJ PH | ||
| Sodium Carbonate | SODIUM CARBONATE | 45P3261C7T | GUM, CHEWING / BUCCAL | 720 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| Potassium Chloride | POTASSIUM CHLORIDE | 660YQ98I10 | SUSPENSION / OPHTHALMIC | 0.03 %w/w | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION/ DROPS / OPHTHALMIC | 1 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / URETHRAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / OPHTHALMIC | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| Potassium Chloride | POTASSIUM CHLORIDE | 660YQ98I10 | POWDER / RESPIRATORY (INHALATION) | 0.18 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | EMULSION / TOPICAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVASCULAR | 0.48 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | GEL / OPHTHALMIC | 0.01 %w/w | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / ORAL | 223 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / OPHTHALMIC | 0.06 %w/v | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | DROPS / NASAL | 10 ml | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.18 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | GEL / VAGINAL | 5 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | JELLY / TOPICAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / TOPICAL | 126 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION/ DROPS / OPHTHALMIC | 0.13 %w/v | ||
| Sodium Carbonate | SODIUM CARBONATE | 45P3261C7T | INJECTION / INFILTRATION | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRA-ARTICULAR | 1 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 4.17 mg | ||
| Sodium Carbonate | SODIUM CARBONATE | 45P3261C7T | SOLUTION / OPHTHALMIC | 0.01 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | ENEMA / RECTAL | 60 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / AURICULAR (OTIC) | 0.04 %w/v | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | TABLET / ORAL | 2.32 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | ADJ PH | ||
| Boric Acid | BORIC ACID | R57ZHV85D4 | SUSPENSION/ DROPS / OPHTHALMIC | 22 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / NASAL | 100 mg/100ml | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / INTRATHECAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / RETROBULBAR | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / SUBCUTANEOUS | 2 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SPRAY / NASAL | 10 ml | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRACARDIAC | 2 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRACAVITARY | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | GEL / TOPICAL | 24 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRACAUDAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 1.5 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, COATED / ORAL | 0.21 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, EMULSION / INTRAVENOUS | 59 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.01 %w/v | ||
| Potassium Chloride | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION, SOLUTION / INTRAVENOUS | 330 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRALESIONAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 6 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / NASAL | ADJ PH |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040164-001 | AKPENTOLATE | CYCLOPENTOLATE HYDROCHLORIDE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 |
| Application-product | TE code |
|---|---|
| A040164-001 | AT |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A040164-001 | AKPENTOLATE | 1% | SOLUTION/DROPS / OPHTHALMIC | AT | 1997-01-13 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040164-001 | AT | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A040164-001 | AT | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A040164-001 | AT | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040164-001 | AT | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040164-001 | AT | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040164-001 | AT | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040164-001 | AT | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040164-001 | AT | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040164-001 | AT | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040164-001 | AT | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040164-001 | AT | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040164-001 | AT | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040164-001 | AT | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040164-001 | AT | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040164-001 | AT | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040164-001 | AT | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040164-001 | AT | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040164-001 | AT | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A040164-001 | AT | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A040164-001 | AT | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A040164-001 | AT | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A040164-001 | AT | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040164-001 | AT | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A040164-001 | AT | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A040164-001 | AT | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A040164-001 | AT | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A040164-001 | AT | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A040164-001 | AT | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A040164-001 | AT | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040164-001 | AT | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A040164-001 | AT | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A040164-001 | AT | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040164-001 | AT | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040164-001 | AT | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040164-001 | AT | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040164-001 | AT | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A040164-001 | AT | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A040164-001 | AT | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040164-001 | AT | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A040164-001 | AT | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 1d97ba11-5b69-4ba3-9310-fa000183de43 | 1d97ba11-5b69-4ba3-9310-fa000183de43 | 2010-09-01 | Warnings, Adverse reactions | 1d97ba11-5b69-4ba3-9310-fa000183de43 1d97ba11-5b69-4ba3-9310-fa000183de43 |
Adverse event summaries are temporarily unavailable. Other product information remains available.